Brief: Zhaoke Ophthalmology Says Positive Top-Line Data From Phase 3 Pivotal BRIO-I Trial Of Brimochol PF
April 25 (Reuters) - Zhaoke Ophthalmology Ltd 6622.HK :
* POSITIVE TOP-LINE DATA FROM PHASE 3 PIVOTAL BRIO-I TRIAL
OF
BRIMOCHOL PF FOR TREATMENT OF PRESBYOPIA
* PHASE 3 PIVOTAL BRIO-I TRIAL. BRIO-I MET PRE-SPECIFIED
PRIMARY
STUDY ENDPOINTS AGREED UPON WITH US-FDA AND EMA/MHRA
Source text for Eikon: ID:nHKS7F9nH4
Further company coverage: 6622.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Zhaoke Ophthalmology
See all newsBrief: Zhaoke Ophthalmology Says Its Facility In Guangzhou Obtains GMP Certification From Australia's TGA
China's Zhaoke Ophthalmology H1 revenue rises
Brief: Zhaoke Ophthalmology Says Yuvezzitm Approved By Macau Pharmaceutical Administration Bureau
Brief: Zhaoke Ophthalmology Enters Into Definitive Agreement For Acquisition Of Global Rights To NVK002
Brief: Zhaoke Ophthalmology Says Yuvezzitm Approved For Use At Boao Super Hospital